In Vitro Microbial Efficacy of Sulbactomax: A Novel Fixed Dose Combination of Ceftriaxone Sulbactam and Ceftriaxone Alone

Shrivastava, Sanjay Mohan; Saurabh, Sandeep; Rai, Dharmendra; Dwivedi, Vivek K.; Chaudhary, Manu

doi:10.2174/157488509787081840

Cited by 14 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of sulbactam and ceftriaxone is active against all the organisms sensitive to ceftriaxone. In addition, it demonstrates synergistic activity (reduction in MIC for the combination versus those of each component) in a variety of organisms (Shrivastava et al, 2009b). There are no pharmacokinetic changes between the two drugs from the compound preparation, and there is no drug interaction between them (Yonghong et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic study of sulbactomax

et al. 2010

Self Cite

View full text Add to dashboard Cite

-We have evaluated pharmacokinetics of a fixed dose combination (FDC) of ceftriaxone and sulbactam (2:1) or sulbactomax in eight healthy volunteers. A 1.5 g dose of sulbactomax, 1 g dose of ceftriaxone and 0.5 g sulbactam were given intravenously in a balanced two-ways cross-over study. Serially collected plasma sample was analyzed for ceftriaxone and sulbactam by high performance liquid chromatography (HPLC). The mean peaks of ceftriaxone and sulbactam concentrations in plasma were 152.06 ± 6.65 μg/ml and 21.32 ± 1.80 μg/ml, respectively and plasma half-lives for ceftriaxone and sulbactam were 5.2 ± 0.35 hr and 0.94 ± 0.038 hr, respectively. The AUC0-24 for ceftriaxone and sulbactam was 760.16 ± 27.68 μg.hr/ml and 20.74 ± 2.34 μg.hr/ml, respectively, with elimination rate constant of 0.133 ± 0.009 hr -1 and 0.732 ± 0.029 hr -1 , respectively. The kinetics of ceftriaxone and sulbactum did not change in combination as compared to the alone treatment. Also, concentration of the ceftriaxone after 24 hr is higher than the minimum inhibitory concentration (MIC) of the most of the gram positive and gram negative bacteria indicating that one dose in a day is sufficient to treat the disease caused by these organisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic study of sulbactomax

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…Time-kill studies were performed in triplicate in 10-ml tubes containing 2 ml of Mueller-Hinton broth, as previously described [21]. In brief, 100 µl of S. aureus suspension was resuspended in 10 ml of Mueller-Hinton broth, incubated overnight at 37°C, and adjusted to a McFarland standard of 0.5.…”

Section: Methodsmentioning

confidence: 99%

Therapeutic Efficacy of Epigallocatechin Gallate-Loaded Nanoliposomes against Burn Wound Infection by Methicillin-Resistant <b><i>Staphylococcus aureus</i></b>

Ghorbanihaghjo¹,

Faezizadeh²,

Godarzee

2012

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Background/Aim: Staphylococcusaureus remains a common cause of burn wound infection. Different studies have shown that the entrapment of plant-derived material such as epigallocatechin gallate (EGCG) in liposomes could increase their anti-S. aureus activity. The objectives of this study were to prepare EGCG-loaded nanoliposomes with variable surface charges and to evaluate their efficacy in vitro and in vivo against methicillin-resistant S. aureus (MRSA). Study Design/Methods: EGCG-loaded nanoliposomes with positive, negative and neutral surface charges were prepared by extrusion method. Minimum inhibitory concentrations (MICs) of EGCG nanoliposomal forms against MRSA were determined by broth dilution method. The killing rates of the free and nanoliposomal forms of EGCG were analyzed. Ultimately, the in vivo therapeutic efficacy of the nanoliposomes in burned mouse skin infected by MRSA was investigated. Results: The MICs of the free, cationic, neutral and anionic nanoliposomal forms of EGCG against MRSA were 128, 16, 32 and 256 mg/l, respectively. The killing rates of the EGCG-loaded cationic nanoliposomes were higher than those of the other formulations. Treatment with the EGCG-loaded nanoliposomes with positive, neutral and negative surface charges resulted in almost 100, 70 and 30% survival rates, respectively. Conclusion: The data suggested that the cationic EGCG-loaded nanoliposomes would be a good choice for the treatment of MRSA infections due to its high effectiveness.

show abstract

“…Time kill studies were preformed in triplicate in 10 ml tubes containing 2 ml of Mueller-Hinton broth as described previously [19]. In brief, 100 μl of P. aeruginosa suspension were resuspended in 10 ml of Mueller-Hinton broth and incubated overnight at 37°C, and adjusted to a McFarland standard of 0.5.…”

Section: Methodsmentioning

confidence: 99%

In vitro and in vivo activities of ticarcillin-loaded nanoliposomes with different surface charges against Pseudomonas aeruginosa (ATCC 29248)

2012

View full text Add to dashboard Cite

BackgroundPseudomonas aeruginosa exhibits multiple antibiotic resistance mechanisms. Different studies have shown that entrapment of antibiotics into liposomes could increase their anti-Pseudomonas activity. The objectives of this study were to prepare ticarcillin loaded-nanoliposomes with variable surface charges and evaluate their in vitro and in vivo efficacies against Pseudomonas aeruginosa (ATCC 29248).MethodsTicarcillin-loaded nanoliposomes with positive, negative and neutral surface charges were prepared by extrusion method. Ticarcillin encapsulation efficacies for different formulations were measured by HPLC method. Minimum inhibitory concentration (MIC) of ticarcillin nanoliposomal forms against strain ATCC 29248 were determined by broth dilution method. The killing rate of Pseudomonas aeruginosa was exposed to various concentrations of ticarcillin in free and nanoliposomal forms were analyzed. Ultimately, in vivo therapeutic efficacy of nanoliposomes in burned mice skin infected with strain ATCC 29248 was investigated.ResultsThe encapsulation efficacies for ticarcillin-loaded cationic nanoliposomes were significantly higher (76% ± 0.17) than those of neutral (55% ± 0.14) and anionic (43% ± 0.14) nanoliposomes. The MIC of free, cationic, neutral and anionic nanoliposomal forms of ticarcillin against ATCC 29248 were to 24, 3, 6 and 48 mg/L, respectively. The killing rates of ticarcillin-loaded cationic nanoliposomes were higher than those of free and other drug formulations. Treatment by ticarcillin-loaded nanoliposomes with positive, neutral and negative surface charges resulted in almost 100, 60 and 20% survival rates, respectively.ConclusionOur data suggested that cationic ticarcillin-loaded nanoliposomes because of high effectiveness would be a good choice to treatment of Pseudomonas aeruginosa infections.

show abstract

In Vitro Microbial Efficacy of Sulbactomax: A Novel Fixed Dose Combination of Ceftriaxone Sulbactam and Ceftriaxone Alone

Cited by 14 publications

References 0 publications

Pharmacokinetic study of sulbactomax

Pharmacokinetic study of sulbactomax

Therapeutic Efficacy of Epigallocatechin Gallate-Loaded Nanoliposomes against Burn Wound Infection by Methicillin-Resistant <b><i>Staphylococcus aureus</i></b>

In vitro and in vivo activities of ticarcillin-loaded nanoliposomes with different surface charges against Pseudomonas aeruginosa (ATCC 29248)

Contact Info

Product

Resources

About